11833 related articles for article (PubMed ID: 12444803)
1. Tumor vaccines: a role in preventing recurrence in melanoma?
Sabel MS; Sondak VK
Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
[TBL] [Abstract][Full Text] [Related]
2. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
4. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
5. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
6. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D; Paschen A; Sun Y
Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
[TBL] [Abstract][Full Text] [Related]
7. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
8. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
9. Update on active specific immunotherapy with melanoma vaccines.
Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
11. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.
Mocellin S; Rossi CR; Nitti D; Lise M; Marincola FM
Biochim Biophys Acta; 2003 Dec; 1653(2):61-71. PubMed ID: 14643925
[TBL] [Abstract][Full Text] [Related]
12. Tumour cell-based vaccines for the treatment of melanoma.
Hsueh EC
BioDrugs; 2001; 15(11):713-20. PubMed ID: 11707146
[TBL] [Abstract][Full Text] [Related]
13. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
14. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
15. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
16. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines.
Ralph SJ
Am J Clin Dermatol; 2007; 8(3):123-41. PubMed ID: 17492842
[TBL] [Abstract][Full Text] [Related]
17. Peptide-based cancer vaccines.
Machiels JP; van Baren N; Marchand M
Semin Oncol; 2002 Oct; 29(5):494-502. PubMed ID: 12407514
[TBL] [Abstract][Full Text] [Related]
18. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
19. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
[TBL] [Abstract][Full Text] [Related]
20. Melanoma vaccines: what we know so far.
Bystryn JC; Reynolds SR
Oncology (Williston Park); 2005 Jan; 19(1):97-108; discussion 108, 111-2, 115. PubMed ID: 15743154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
